Fortis Healthcare Limited will host a conference call on Friday, August 07, 2026, at 11:00 am IST to discuss its unaudited financial results for the quarter ended June 30, 2026. This disclosure ensures transparency for investors and analysts regarding the company’s performance in Q1FY27. The meeting aims to provide clarity on operational metrics and financial health, allowing stakeholders to assess the healthcare provider's trajectory in the current fiscal year.

The announcement was made on July 30, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Satyendra Chauhan, Company Secretary & Compliance Officer, signed the intimation submitted to both the National Stock Exchange of India Ltd. and BSE Limited. The filing confirms that no Unpublished Price Sensitive Information (UPSI) will be shared during the proceedings, adhering to regulatory standards for fair disclosure.

Conference Call Details

The session is structured as a virtual group call, accessible to investors and analysts from India and international markets. Management will address queries regarding the Q1FY27 performance, offering insights into revenue streams, patient footfall, and margin dynamics without revealing any price-sensitive data prior to the official release.

Participants can join via the provided dial-in numbers or through the Express Join link using DiamondPass™ to avoid operator wait times. For those unable to attend live, a replay of the conference call will be available from August 07, 2026, to August 14, 2026. The replay can be accessed by calling +91 22 7194 5757 and entering the playback ID: 27619.

What the Numbers Show

While specific financial figures were not disclosed in this scheduling notice, the timing of the call indicates that Fortis Healthcare has completed its internal review of Q1FY27 results. Investors should monitor the subsequent exchange filings for detailed metrics on net profit, revenue from operations, and EBITDA margins. The focus during the call is expected to be on explaining variances from previous periods and outlining strategic initiatives for the remainder of FY27.

Fortis Healthcare Limited has fixed Friday, July 24, 2026, as the record date to determine shareholder eligibility for a final dividend of ₹1 per equity share. The dividend, equivalent to 10% of the face value of ₹10 each, is recommended for the financial year 2025-26 and is subject to the approval of members at the 30th Annual General Meeting scheduled for Tuesday, August 11, 2026. The company has intimated that the dividend will be paid subject to the deduction of Tax at Source (TDS) in accordance with the Income Tax Act, 2025.

The Register of Members and Share Transfer Books will remain closed from Saturday, July 25, 2026, to Tuesday, August 11, 2026. Shareholders are requested to ensure that details such as PAN, residential status, category, and bank account information are updated in their demat accounts or folios by submitting Form ISR-1 to the Registrar and Share Transfer Agent, KFin Technologies Limited. To avail benefits of exemption or lower tax deduction, shareholders must submit necessary declarations and supporting documents on or before August 5, 2026.

Tax Deduction Rates

For resident shareholders, tax will be deducted at 10% if a valid PAN is registered. If the shareholder is a specified person or has provided an inoperative PAN, TDS will be deducted at 20%. Resident individuals are exempt from TDS if the aggregate dividend distributed during the financial year does not exceed ₹10,000. Non-resident shareholders, including Foreign Portfolio Investors, face a withholding tax rate of 20% plus applicable surcharge and cess, unless they opt for benefits under the Double Tax Avoidance Agreement (DTAA).

Compliance and Submission

Shareholders seeking lower or nil TDS must submit self-declarations and documents via the weblink provided by KFin Technologies or via email. Non-resident shareholders claiming DTAA benefits must provide a Tax Residence Certificate, Form 41, and a self-declaration certifying tax residency and eligibility. The company emphasized that it will rely on data available with the depositories and the RTA as of the record date, and no requests for revision of TDS returns will be entertained.

The intimation was made in compliance with Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.